PCA3
- Aliases
-
- DD3
- NCRNA00019
- PCA3
- PCAT3
- non-protein coding RNA 19
- prostate cancer antigen 3
- prostate cancer antigen 3 (non-protein coding)
- prostate cancer associated transcript 3 (non-protein coding)
- Description
- The prostate cancer antigen 3 (PCA3) gene is a highly specific biomarker upregulated in prostate cancer. Because there is no extensive open reading frame, the gene is thought to express a noncoding RNA. The FDA has approved an assay for prostate cancer that uses the ratio of PCA3 RNA to PSA RNA in urine. The assay is used to help physicians determine the need for repeat prostate biopsies in men 50 years of age or older who have had a previous negative biopsy. When used in conjunction with other clinical information, the use of this test can reduce the need for unnecessary prostate biopsies.
Attributes
- QA State
- Curated
- Type
- Gene
- HGNC Name
- PCA3
- Certifications
- QA State for Prostate
- Curated
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.
- Can urinary PCA3 supplement PSA in the early detection of prostate cancer?
- Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
- Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.
- Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
- Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
- Rational approach to implementation of prostate cancer antigen 3 into clinical care.
- Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.